ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last481 to 500 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of Coronary Revascularisation473 of 8,803

608 of 8,801

-1.5 points

-2.2 to -0.8

17,604NCT03574597

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of HF Requiring Hospitalisation or Urgent HF Visit97 of 8,803

122 of 8,801

-0.3 points

-0.6 to 0.0

17,604NCT03574597

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Semaglutide vs Placebo: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke569 of 8,803

701 of 8,801

-1.5 points

-2.3 to -0.7

17,604NCT03574597

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of Non-fatal Stroke154 of 8,803

165 of 8,801

-0.1 points

-0.5 to 0.3

17,604NCT03574597

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of a Composite Outcome Measure Consisting of: All-cause Death, Non-fatal MI, or Non-fatal Stroke710 of 8,803

877 of 8,801

-1.9 points

-2.7 to -1.1

17,604NCT03574597

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of a 5-component Composite Nephropathy Outcome Measure155 of 8,803

198 of 8,801

-0.5 points

-0.9 to -0.1

17,604NCT03574597

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Semaglutide vs Placebo: Participants From Time of Randomisation to CV Death223 of 8,803

262 of 8,801

-0.4 points

-0.9 to 0.0

17,604NCT03574597

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of UAP Requiring Hospitalisation109 of 8,803

124 of 8,801

-0.2 points

-0.5 to 0.2

17,604NCT03574597

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of Non-fatal MI234 of 8,803

322 of 8,801

-1.0 points

-1.5 to -0.5

17,604NCT03574597

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of an Expanded Composite CV Outcome Measure Consisting of: CV Death, Non-fatal MI, Non-fatal Stroke, Coronary Revascularisation or Unstable Angina Pectoris (UAP) Requiring Hospitalisation873 of 8,803

1,074 of 8,801

-2.3 points

-3.2 to -1.4

17,604NCT03574597

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Semaglutide vs Placebo: deaths from any cause371 of 8,803

460 of 8,801

-1.0 points

-1.6 to -0.4

17,604NCT03574597

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of a Composite Heart Failure (HF) Outcome Measure Consisting of: HF Hospitalisation, Urgent HF Visit or CV Death300 of 8,803

361 of 8,801

-0.7 points

-1.3 to -0.1

17,604NCT03574597

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Semaglutide vs Placebo: Participants From Time of Randomisation to All-cause Death375 of 8,803

458 of 8,801

-0.9 points

-1.6 to -0.3

17,604NCT03574597

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Semaglutide vs Placebo: serious adverse events2,941 of 8,803

3,204 of 8,801

-3.0 points

-4.4 to -1.6

17,604NCT03574597

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of Glycosylated Haemoglobin (HbA1c) Greater Than Equals to (≥) 48 Millimole Per Mole (mmol/Mol) (6.5 Percentage [%])306 of 8,800

1,059 of 8,797

-8.6 points

-9.3 to -7.8

17,597NCT03574597

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

ACP Video Program vs Usual ACP Procedures: Proportion of Long-stay Residents Without Advanced Illness With Any Hospice Enrollment373 of 5,766

832 of 11,782

-0.6 points

-1.4 to 0.2

17,548NCT02612688

Pragmatic Trial of Video Education in Nursing Homes

ACP Video Program vs Usual ACP Procedures: Proportion of Long-stay Residents Without Advanced Illness Receiving Any Burdensome Treatment465 of 5,766

1,028 of 11,782

-0.7 points

-1.5 to 0.2

17,548NCT02612688

Pragmatic Trial of Video Education in Nursing Homes

ACP Video Program vs Usual ACP Procedures: Proportion of Long-stay Residents Without Advanced Illness That Has Medicare ACP Billing Codes571 of 5,766

1,157 of 11,782

0.1 points

-0.8 to 1.0

17,548NCT02612688

Pragmatic Trial of Video Education in Nursing Homes

Zoster-022/006 Pooled GSK1437173A Group vs Zoster-022/006 Pooled Placebo Group: Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Fatal SAEs128 of 8,758

144 of 8,773

-0.2 points

-0.5 to 0.2

17,531NCT01165229

Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older

S-268019-b vs Placebo: deaths from any cause29 of 9,083

29 of 8,435

-0.0 points

-0.2 to 0.1

17,518NCT05212948

A Study of S-268019 for the Prevention of COVID-19

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=25

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03574597-0c2be2f1",
        "title": "Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of Coronary Revascularisation",
        "summary": "473 of 8803 against 608 of 8801; risk difference -1.5 points, 95% interval -2.2 to -0.8; NCT03574597, Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity",
        "record": "/library/comparisons/NCT03574597-0c2be2f1",
        "nct_id": "NCT03574597",
        "kind": "outcome",
        "participants": 17604,
        "risk_difference": {
          "value": -0.015351376362318155,
          "lower": -0.02246055340225811,
          "upper": -0.00826445609801518
        },
        "group_1": "473 of 8,803",
        "group_2": "608 of 8,801",
        "difference": "-1.5 points",
        "interval": "-2.2 to -0.8",
        "trial_title": "Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity"
      },
      {
        "id": "NCT03574597-19f20c85",
        "title": "Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of HF Requiring Hospitalisation or Urgent HF Visit",
        "summary": "97 of 8803 against 122 of 8801; risk difference -0.3 points, 95% interval -0.6 to 0.0; NCT03574597, Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity",
        "record": "/library/comparisons/NCT03574597-19f20c85",
        "nct_id": "NCT03574597",
        "kind": "outcome",
        "participants": 17604,
        "risk_difference": {
          "value": -0.0028430903240098636,
          "lower": -0.00616028139390796,
          "upper": 0.00044218503694354056
        },
        "group_1": "97 of 8,803",
        "group_2": "122 of 8,801",
        "difference": "-0.3 points",
        "interval": "-0.6 to 0.0",
        "trial_title": "Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=26",
  "request_id": "A9c9_jMStlQtjCsF"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?